The Dynamic Monitoring of Cerebrospinal Fluid ctDNA - Trial NCT06315686
Access comprehensive clinical trial information for NCT06315686 through Pure Global AI's free database. This Phase 2 trial is sponsored by Jiangsu Province Nanjing Brain Hospital and is currently Recruiting. The study focuses on NSCLC. Target enrollment is 20 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Jiangsu Province Nanjing Brain Hospital
Timeline & Enrollment
Phase 2
Sep 29, 2022
Dec 31, 2024
Primary Outcome
The progression-free survival time๏ผPFS๏ผ
Summary
Focusing on advanced EGFR mutation in NSCLC patients with leptomeningeal metastasis,
 vormetinib combined with OMMAYA lateral ventricle chemotherapy (pemetrexed) was used to
 dynamically monitor ctDNA in cerebrospinal fluid (CSF), analyze the ctDNA gene mutation
 profile of CSF in different patients, and explore the relationship between ctDNA and efficacy
 and prognosis.
Data Source
ClinicalTrials.gov
NCT06315686
Non-Device Trial